Lifecore Biomedical’s (LFCR) “Equal Weight” Rating Reaffirmed at Stephens

Stephens reissued their equal weight rating on shares of Lifecore Biomedical (NASDAQ:LFCR) in a research note published on Friday morning,Benzinga reports. Stephens currently has a $6.00 price objective on the stock.

Separately, Craig Hallum increased their target price on Lifecore Biomedical from $8.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, November 22nd.

Lifecore Biomedical Stock Up 14.4 %

NASDAQ LFCR opened at $7.62 on Friday. The company has a debt-to-equity ratio of 12.90, a quick ratio of 0.80 and a current ratio of 1.83. The company has a market capitalization of $280.62 million, a P/E ratio of 95.25 and a beta of 0.98. Lifecore Biomedical has a one year low of $3.68 and a one year high of $8.90. The stock has a 50 day moving average price of $7.03 and a 200-day moving average price of $5.79.

Lifecore Biomedical (NASDAQ:LFCR) last posted its earnings results on Thursday, January 2nd. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.02. Lifecore Biomedical had a negative return on equity of 382.65% and a net margin of 5.09%. As a group, equities analysts predict that Lifecore Biomedical will post -0.99 EPS for the current fiscal year.

Institutional Trading of Lifecore Biomedical

A number of institutional investors have recently bought and sold shares of LFCR. Bank of New York Mellon Corp bought a new stake in Lifecore Biomedical in the second quarter worth $327,000. Rhumbline Advisers lifted its position in Lifecore Biomedical by 1,668.5% in the second quarter. Rhumbline Advisers now owns 26,899 shares of the company’s stock worth $138,000 after buying an additional 25,378 shares during the last quarter. Renaissance Technologies LLC bought a new stake in Lifecore Biomedical in the second quarter worth $56,000. DCF Advisers LLC lifted its position in Lifecore Biomedical by 2.1% in the second quarter. DCF Advisers LLC now owns 290,684 shares of the company’s stock worth $1,491,000 after buying an additional 6,000 shares during the last quarter. Finally, Marshall Wace LLP lifted its position in Lifecore Biomedical by 87.3% in the second quarter. Marshall Wace LLP now owns 300,120 shares of the company’s stock worth $1,540,000 after buying an additional 139,887 shares during the last quarter. 83.36% of the stock is currently owned by institutional investors.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.